BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother 2020;64:e01463-20. [PMID: 32868329 DOI: 10.1128/AAC.01463-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Cheng J, Viswanathan U, Chang J, Lu F, Guo JT. Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis. PLoS Pathog 2021;17:e1010057. [PMID: 34752483 DOI: 10.1371/journal.ppat.1010057] [Reference Citation Analysis]
2 Kim H, Ko C, Lee JY, Kim M. Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules 2021;26:7420. [PMID: 34946502 DOI: 10.3390/molecules26247420] [Reference Citation Analysis]
3 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zuccaro V, Asperges E, Colaneri M, Marvulli LN, Bruno R. HBV and HDV: New Treatments on the Horizon. J Clin Med 2021;10:4054. [PMID: 34575165 DOI: 10.3390/jcm10184054] [Reference Citation Analysis]
5 Lv K, Wu S, Tao Z, Wang A, Xu S, Yang L, Gao Q, Wang A, Qin X, Jiang B, Wu W, Jia X, Li Y, Jiang J, Liu M. Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators. Eur J Med Chem 2021;:113974. [PMID: 34772528 DOI: 10.1016/j.ejmech.2021.113974] [Reference Citation Analysis]
6 Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection. J Hepatol 2022:S0168-8278(22)00238-0. [PMID: 35460726 DOI: 10.1016/j.jhep.2022.04.005] [Reference Citation Analysis]
7 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vermes T, Kielpinski M, Henkel T, Pericàs MA, Alza E, Corcuera A, Buschmann H, Goldner T, Urban A. An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. Anal Methods 2021. [PMID: 34918017 DOI: 10.1039/d1ay01227d] [Reference Citation Analysis]
9 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res 2021;197:105211. [PMID: 34826506 DOI: 10.1016/j.antiviral.2021.105211] [Reference Citation Analysis]